



## Kura Oncology to Participate in SVB Securities Global Biopharma Conference

February 7, 2023

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 5:00 p.m. ET / 2:00 p.m. PT on February 14, 2023.

A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com), with an archived replay available following the event.

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a potent and selective menin inhibitor, is currently in development for patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3K $\alpha$  inhibitor apelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3K $\alpha$  pathways. The Company has also initiated a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in EGFR-mutant non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company's next-generation FTI, through a Phase 1 first-in-human study. For additional information, please visit Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### Contacts

Investors:

Pete De Spain

Senior Vice President, Investor Relations &  
Corporate Communications

(858) 500-8803

[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

Media:

Alexandra Weingarten

Senior Manager, Corporate Communications

(858) 500-8822

[alexandra@kuraoncology.com](mailto:alexandra@kuraoncology.com)



Source: Kura Oncology, Inc.